Member Info for LovableLumax

This is a safety study on end of life patients who have exhausted all other options so efficacy not expected so the fact many lives have been extended really something and little wonder the investigators so excited.

Well we know revenue for H1 was down 1/3rd to £400,000 which to me suggests the cash burn is up. We have had no material RNSs all the while the CEO pocketed more than half the H1 revenue.

So end of August likely just over £7m and remember they had over £6m at last year end and in order for the auditor to sign off accounts they’ll need a year’s cash. A raise has to be nailed on and surely they won’t leave it as late this time.

It’s pretty amazing many of these end of life patients who have had prior treatments that were unsuccessful have had their lives extended and without the usual awful side effects. Delivering more drug to the tumour and stroma without the debilitating side effects. Working as designed and as if did pre-clinical which will give even more weight to the preclinical pipeline work. An exciting few weeks and months ahead.

Yep I remember that as was there. The data backs it up but also we didn’t know it could be effective when no FAP in cancer cells which shows how super the specificity is. Again, I suspect this is from FAPI-PET which was a new study.

Touk you have said numerous times there was no info and you maintained that position when I pointed out the exciting case studies with Tumor histology demonstrating no expression of FAP in tumor cells with only stromal cell expression noted so 6000 cleaving on stroma which is fantastic and has not been mentioned (or likely known by the co) before. Perhaps FAPI-PET helped. You said yourself this is excellent news.

Also, we know the half-life doesn’t need modifying as it sticks around 40% more than normal dox which isn’t a surprise given the 24 hour biopsy data. I know that was something you were concerned with.

Given the super news above and elsewhere I’m sure you can enjoy your holiday even more ;)

You said -

Lovable

Excellent though that is, it is not new. It was reported in a previous update.

But yes it is excellent

I can’t find this in the previous update or any others. Did you pretend it isn’t new or can you show me where it was published before? As below this is a real USP as we know the stroma is key a quick search -

Cancer treatment that targets the stroma is an emerging area of research, and current strategies are still being developed. The stroma is a combination of connective tissue and cells that supports other functional tissues. It plays a key role in tumorigenesis, cancer progression, metastasis, and therapy resistance

https://x.com/blueberrymgmnt/status/1835073677731188968?s=46

Christina

Touk, I can’t see that in the AACR info. Can you direct me to it or any info RNSs before now?

Look at the poster, there is a chart. You can compare to AACR.

Also, the below is key and touk was asking for new info and this is superb.

https://x.com/blueberrymgmnt/status/1835073677731188968?s=46

If £700k burn continues and they have less than £8.4m at June 30 they will have less than a year’s cash from June 30 and they would be crazy to leave it late to raise cash as they’ll get their trousers pulled down again. Surely a raise worked on end of this year for early next.

Lots of sells above mid price which is positive

Their costs aren’t far off £1m a month so without programmatic and a serious uptick in revenues a raise will be needed. More alienated IIs and retail fed up so very hard for them to raise with a CEO who said st the last raise programmatic ready in June for a few weeks later to say it’s been delayed he’s lost even more credibility.

Interim report will be interesting but it’s better to leave the table with something than nothing. That said if proframmmatic launches in the next couple of weeks if could recover but if not it will surely fall even further before they try and raise at a large discount.

Okay I phrased that incorrectly. Of course they would have to approve but it would be a fait accompli and it certainly wasn’t put like that. Anyway, we should have news on cohorts 1 and 2 of 2 weekly on Monday so we’ll see how it’s going and we should know whether we stopped at cohort 3 and have found the optimum regimes. Surely that’s the case.!

If FDA asked for 2 weekly dosing we would not have said it was subject to their approval before we could start.

That sounds ominous but not a fait accompli. Unless programmatic rolled out imminently they will miss the bust Q4 period and the BoD will know a raise inevitable. It’ll be at another discount so if that’s the case they’ll look to sell as an option. They should have £8m cash but there will be creditors, I suspect the BoD on 12 months notice so they’ll get paid off and senior staff will be on 6 months and others likely 3 months so I guess there won’t be a lot of change.

The CEO has not stopped being dishonest all the while taking £500k a year when as a MD of a small marketing co (turnover of £2m) he’d be on £100k with dividends on profit.

It sounds like phevs has dumped a fair number. We’ve seen this before.

Thorn you either don’t understand the data or you’re disingenuous. You must be short to spend so much time on here talking nonsense. Get a life FFS.

Let’s see what Monday brings but I certainly trust the scientists and the data more than you. They wouldn’t say AVA6000 was working and didn’t need modifying if that wants the case. This is a new board so that would have been their chance to blame the past regime and say it needs changing. Alas it doesn’t as the large amounts of dox in tumour at 24 hours says. You clearly have an agenda. Fair enough but it’s funny you think you can interpret the data better than those with PHDs and working on the platform.

I look forward to Monday and hopefully soon after the pipeline reveal.

Yes and given there is large amounts of dox in the tumour at 24 hours indicates the delivering mechanism isn’t excreted too quickly. Normal dox is excreted within 20-30 hours and there will be a lot less making its way to the tumour. Again, lots of papers on dox’s half life. You might be able to argue if our biopsies were taken after a few hours but at 24 you have no case.

Blimey take a look at doxorubicin’s half life. Lots of papers on it. 6000 is depositing lots of dox and loads 24 hours after dosing when most dox is cleared then when administered ‘noramlly’z

Wow, different molecules or warheads are excreted at different speeds than others. Dox hangs around long enough so doesn’t need changing but other war heads in development need amending in order to extend.

We have heard it from the scientists who I don’t think are lying or misunderstand the data. I’m sure the FDA agrees given they have allowed the 2 weekly trial.

In addition the biopsies taken 24 hours after dosing demonstrate all is well. Amazing some t think they understand the data more than the scientists working on the platform.